Inhibition of Fructosamine Oxidase in Diabetic Nephropathy (INFO-Renal) Study
Study to assess whether treatment with GC811007 would arrest the decline in renal function and the associated progression of diabetic retinopathy, peripheral neuropathy and autonomic neuropathy in patients with Type 2 diabetes mellitus.
Protemix Corporation, Ltd.
120 participants
Nov 8, 2001
Interventional
Conditions
Summary
This pilot study was designed to assess whether treatment with GC811007 would arrest the decline in renal function and the associated progression of diabetic retinopathy, peripheral neuropathy and autonomic neuropathy in patients with Type 2 diabetes mellitus. The safety and tolerability of GC811007 also were assessed.
Eligibility
Inclusion Criteria1
- Men and women between 30 to 70 years of age with poor blood glucose control, retinopathy and nephropathy resulting from Type 2 diabetes mellitus.
Exclusion Criteria1
- Healthy volunteers excluded, and those with with poor blood glucose control, retinopathy and nephropathy resulting from Type 2 diabetes mellitus, but outside of the age range above
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This was a randomized, double-blind, Placebo-controlled study in adult patients with diabetic nephropathy. Upon completion of screening, Enrolment and a 3-week Placebo-run-in period, patients were randomized to treatment with 1200 mg/day, GC811007 (taken as two 300-mg capsules twice daily, BID, before meals) or Placebo, administered as 2 identical 300-mg capsules taken orally twice daily (BID) before meals for 6 months. Patients underwent safety and efficacy assessments during clinic visits at Months 0, 2, 4, and 6. Telephone follow-up interviews were conducted 2 weeks after the final clinic visit.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000959875